Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance-Reference-Cited by-同舟云学术

Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance

Published:2000-01 Issue:1 Volume:32 Page:43-50
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Kojima Hideyuki,Yamao Jyunichi,Tsujimoto Tatsuhiro,Uemura Masahito,Takaya Akira,Fukui Hiroshi

Publisher

Elsevier BV

Subject

Hepatology

Reference34 articles.

1. Liver function and pharmacological considerations in the pathogenesis and treatment of portal hypertension;Reichen;Hepatology,1990

2. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension;Vorobioff;Am J Physiol,1983

3. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis;Uchihara;Hepatology,1992

4. Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites;Leivas;Gastroenterology,1995

5. Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats;Gandhi;Life Sci,1996

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GARP on hepatic stellate cells is essential for the development of liver fibrosis;Journal of Hepatology;2023-11

2. Emerging Therapeutic Targets for Portal Hypertension;Current Hepatology Reports;2023-02-11

3. Endothelin receptor B enhances liver injury and pro-inflammatory responses by increasing G-protein-coupled receptor kinase-2 expression in primary biliary cholangitis;Scientific Reports;2022-11-17

4. Endothelins and liver cirrhosis;Portal Hypertension & Cirrhosis;2022-06

5. Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH;Disease Models & Mechanisms;2021-05-01